Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to examine whether regorafenib treatment can help people
with gastrointestinal stromal tumours (GIST) and have gene mutation on c-kit exon 17. The
safety of regorafenib treatment is also examined.